F amily studies have for decades documented a critical role of both common and rare inherited variations contributing to interindividual differences in the risks of common heart, lung and blood diseases and their risk factors. Examples include Mendelian forms of disease such as familial hypercholesterolemia caused by low-density lipoprotein receptor mutations and hypertension resulting from epithelial sodium channel subunit mutations. For most conditions, however, the identity of the contributing loci and allelic variants has remained elusive. In the late 1990s, 2 unlikely scientific tools were combined to seed a revolution in gene and locus discovery for many common disease traits. First, the HapMap Project (www.hapmap.org) produced a collection of haplotype-tagging variants that could capture information across the entire genome in common variants potentially influencing risk to disease. Second, large deeply phenotyped cohort studies in both the United States and Europe formed collaborations that took advantage of available DNA, appropriate informed consent, and high-quality longitudinal information about multiple phenotypes. 1 These tools formed the basis of many genome-wide association studies (GWAS) which have identified hundreds of loci underlying common chronic conditions, infectious diseases, and cancer susceptibilities (www. genome.gov/gwastudies/).
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Because of the small effect sizes expected for most loci of interest, the large number of marker loci measured, and thus the corresponding number of statistical tests, large sample sizes are the norm for most contemporary GWAS. To obtain such sample sizes, multiple groups and studies have combined to form collaborative consortia. For instance, Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) 1 Consortium, which focuses on the genetics of cardiovascular disease and aging, has produced more than 300 publications reporting the results of GWAS for many cardio-, renal-, and cerebrovascular disease-related traits, including metabolic and inflammation traits. Several commentators have raised questions about the utility of GWAS, which have been celebrated because they have successfully identified genetic loci contributing to many diseases and conditions 2 and maligned because these loci account for little of the heritability underlying the traits of interest. 3 A major focus of the unbiased search for new genetic loci is not prediction of disease risk but the discovery of new biology. Nevertheless, the utility of GWAS results for understanding the biology or epidemiology of disease is compromised because the method intrinsically does not definitively identify the causative genes or genomic motifs nor does it identify the contributing functional allelic variations that are necessary to make progress toward the 3 translational goals of human genomics: improved diagnostics, improved drug discovery, and tailored treatments. Detailed information about the identity and allelic spectrum at the contributing loci enhances our understanding of the genetic architecture of the traits of interest. Circulation Cardiovascular Genetics has published the results of multiple investigations describing the results of CHARGE Targeted Sequencing studies. In this perspective, without repeating or summarizing their findings, we attempt to provide a critical assessment of the CHARGE Targeted Sequencing Study effort and what was learned from the experiment.
The relative contribution of common versus rare variants to phenotypic variance and, by extension, the heritability of the phenotype remains an area of active debate and discussion. 4 The results of CHARGE Targeted Sequencing studies contribute new information to this dialogue, although it is limited because the loci were selected on the basis of GWAS results and are therefore biased toward common variants in linkage disequilibrium with commercial array marker loci. For some of the targeted loci reported in this issue, a role for rare or lowfrequency variations emerged in addition to the contribution of common variants. Given these results, it is unlikely that a predominant mechanism for many GWAS findings is a synthetic association resulting from the combined effects of rare variants. 5 Most likely, the phenomenon does occur, but it is not a predominant mechanism. There is not enough information in the results provided to evaluate the relative contribution of common versus rare variants for these traits, and the final result will most likely be both trait and population dependent.
The statistical framework for GWAS follow-up remains an important and relatively understudied area. In view of the fact that the original GWAS rejected the null hypothesis of no effect, subalternative hypotheses related to the biological nature of the newly discovered effects include, for instance, one common causative variant, multiple common causative variants, or a synthetic association resulting from multiple rare variants. Evaluating these and other alternative hypotheses does not pose the same scale of multiple-testing problem encountered by the original genome-wide study, but evaluating the evidence for or against each of these competing explanations is not amenable to a straightforward significance-testing screen. 6 Indeed, emerging evidence suggests that a particular gene or other functional motif may have more than one functional common variant and may also host rare potentially functional variations, so that many loci may encode a combination of these alternative hypotheses. Furthermore, the variant providing the smallest P-value is not necessarily causative or functional. 7 Statistical methods and criteria for identifying which variants are causal are emerging, and examples are included in this issue. It remains unclear whether default analyses for follow-up can be established, or whether the literature must accept tailored approaches for each combination of loci and phenotype.
A recurring recommendation from the authors of these studies is the need for larger sample sizes. Sample sizes on the order of tens of thousands have become routine for most published GWAS. It seems from these studies and a synthesis of recent whole exome analyses 8 that similarly large samples may be necessary to confidently evaluate the association between sequence variation and complex traits. The CHARGE Targeted Sequencing Study used a case-cohort design, which is well known for efficiency, although some power may have been lost for the most common phenotypes. 9 By selecting cases from the extremes of the distribution, the power of the study should be increased, especially for the analysis of rare variants. In some cases, meta-phenotypes that are correlated with the clinical phenotype of interest but are closer to the gene level in the hierarchy of biological organization may have larger gene effects that improve power. Combining the field of metabolomics with GWAS may be particularly informative in this respect; Suhre et al 10 and Yu et al 11 reported the results of GWAS of untargeted metabolomics that revealed important insight into diabetes mellitus and chronic kidney disease.
Much of the primary gene discovery work has been done in samples of European descent. CHARGE Consortium has expanded gene discovery into non-European descended populations, investigated the transferability of GWAS loci across populations, and performed fine-mapping of GWAS loci. 12, 13 Expanding the repertoire of ethnic diversity not only permits the investigation of alleles that may be private to one group or another but also enables the investigators to leverage differences in linkage disequilibrium and gene-environment interactions among groups.
The CHARGE Targeted Sequencing studies relied heavily on state-of-the-art statistical analysis to guide scientific discovery. GWAS signals often contain more than 1 gene and heuristic arguments are often used to prefer one gene over others. In addition, linkage disequilibrium often spans the same set of genes so association-based methods are not able to distinguish the effect of one gene from another. Sequence information and statistical analysis, which can move the field only to date, nonetheless provide a set of potentially functional variants that are best evaluated in experimental follow-up studies, including animal model studies and in vitro cell-based systems. 14 Combining a statistical approach based on observational human data with an experimental approach provides genuinely new sources of information, aids in the internal validation of existing information, and opens the door for new lines of investigation. If an appropriate phenotype exists that recapitulates the human condition, animal model studies are ideal to distinguish the impact of whole gene loss of function or gain of function mutants on a phenotype. In cardiovascular diseases involving action potentials and ECG parameters, for instance, the zebrafish has proven particularly useful as a rapid screening tool. 15 Similarly, Drosophila has been used successfully to evaluate GWAS signals for several neurocognitive traits. 16 For cardiovascular diseases, Musunuru et al used a series of cell line and mouse experiments to show that a single variant in the SORT1 gene, rs12740374, influences SORT1 transcription and low-density lipoprotein cholesterol and very low-density lipoprotein cholesterol metabolism. 17 The publications by Musunuru and similar efforts 18 are bright lights that help define future directions. Such detailed experimental studies are laborious and time consuming, and development of high-throughput functional pipelines, such as that facilitated by CRISPR, 19 would be a welcome addition to the scientific repertoire.
The targeted sequencing studies published in Circulation Cardiovascular Genetics represent a first step toward leveraging the power of next-generation sequencing technologies to identify the genes and variants underlying published GWAS signals. Expanded efforts in whole exome capture sequencing and whole genome sequencing are sure to follow. The public health challenge is not gene discovery but translating the new genomic and other -omic information to reduce the burden of cardiovascular disease on the health of the public. The advent of healthcare reform and an aging and unhealthy population makes continued searches for novel treatments and prevention strategies even more important in the near future. Existing large population studies provide an informative and cost-effective setting to examine the impact of genomic information on clinical outcomes, and a scientific commons that includes genotype, phenotype, and outcomes information will accelerate discovery, biology, and improved public health. 20 
